Celgene Has Something Investors Want - Growth

Celgene Corporation (CELG) is a biopharmaceutical company focused on development, and commercialization of therapies to treat a broad range of cancer and immune-inflammatory related conditions.

It is a fast growing biotech with much of its growth coming from a relatively newly approved drug named Revlimid which treats some types of bone marrow and blood cancers. However it also has several large product lines, including Thalomid and Alkeran, which also treat blood cancers.

Additionally the company also receives revenue from Ritalin and Focalin royalties (popular attention deficit disorder treatments), and has several clinical trials for various cancer, psoriasis, and arthritis drugs in the pipeline.

"After three years as a bear market, biotech can be bought” (Jim Cramer, who is bullish on Celgene (CELG), Gilead (GILD), and Cephalon (CEPH)).

Although Celgene looks expensive here with a 182 PE, Celgene has something investors want…growth. Celgene grew its earnings per share 475% over the past 12 months [YOY]. Revenues have also grown 76% over that same time. My recommendation is to buy this stock.

Disclosure: Author has a long position in CELG